Dennis P. Morgan, MD - University of ...

Dr. Dennis P. Morgan

Claim this profile

University of Mississippi Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied

Area of expertise

1

Lung Cancer

Dennis P. Morgan has run 7 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
Stage I
2

Non-Small Cell Lung Cancer

Dennis P. Morgan has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.

University Of Mississippi Medical Center

Clinical Trials Dennis P. Morgan is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Dennis P. Morgan

Clinical Trial Related

6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Dennis P. Morgan has experience with

  • Pembrolizumab
  • Talazoparib
  • Carboplatin
  • Paclitaxel
  • Ramucirumab
  • Gemcitabine Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Dennis P. Morgan specialize in?

Is Dennis P. Morgan currently recruiting for clinical trials?

Are there any treatments that Dennis P. Morgan has studied deeply?

What is the best way to schedule an appointment with Dennis P. Morgan?

What is the office address of Dennis P. Morgan?

Is there any support for travel costs?